IN2014DN03077A - - Google Patents

Info

Publication number
IN2014DN03077A
IN2014DN03077A IN3077DEN2014A IN2014DN03077A IN 2014DN03077 A IN2014DN03077 A IN 2014DN03077A IN 3077DEN2014 A IN3077DEN2014 A IN 3077DEN2014A IN 2014DN03077 A IN2014DN03077 A IN 2014DN03077A
Authority
IN
India
Prior art keywords
sirt2
methods
assay
practicing
kits
Prior art date
Application number
Inventor
Hening Lin
Bin He
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of IN2014DN03077A publication Critical patent/IN2014DN03077A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The instant application describes novel compounds that modulate (in particular inhibit) Sirt2 with structures according to Formulas (1) and (2) provided herein. The invention is also directed to pharmaceutical compositions thereof methods of treatment (i.e. cancer and neurodegenerative disease) by administration of the modulating compounds assay methods for finding modulators of Sirt2 and kits for practicing the assay method.
IN3077DEN2014 2011-10-07 2012-10-05 IN2014DN03077A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161544452P 2011-10-07 2011-10-07
PCT/US2012/058846 WO2013052727A1 (en) 2011-10-07 2012-10-05 Methods of treatment using modulators of sirt2

Publications (1)

Publication Number Publication Date
IN2014DN03077A true IN2014DN03077A (en) 2015-05-15

Family

ID=48044173

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3077DEN2014 IN2014DN03077A (en) 2011-10-07 2012-10-05

Country Status (6)

Country Link
US (2) US9359293B2 (en)
EP (1) EP2763962B1 (en)
CN (2) CN110143900B (en)
ES (1) ES2773266T3 (en)
IN (1) IN2014DN03077A (en)
WO (1) WO2013052727A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2763962B1 (en) * 2011-10-07 2019-12-04 Cornell University Methods of treatment using modulators of sirt2
US9945865B2 (en) * 2013-03-22 2018-04-17 University Of Florida Research Foundation, Inc. Polymer nanocomposites for early diagnosis of diseases
WO2014197775A1 (en) * 2013-06-06 2014-12-11 Cornell University Thiourea compounds and their use as inhibitors of sirt2 or sirt5
WO2018144864A1 (en) * 2017-02-03 2018-08-09 The Mclean Hospital Corporation Methods for manipulating cell fate
CN110551048B (en) * 2018-06-04 2021-08-10 中国科学院上海药物研究所 SIRT2 inhibitor, preparation method and application thereof
US12161639B2 (en) 2018-07-17 2024-12-10 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating PACS1 and PACS2 syndromes
CN114315670B (en) * 2022-01-19 2024-03-29 贵州医科大学 SIRT2/HDAC6 double-target inhibitor and application thereof
CN116178340B (en) * 2023-04-28 2023-08-18 细胞生态海河实验室 PROTAC compound, preparation method and pharmaceutical composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063008A1 (en) 2000-12-16 2002-06-20 Merck Patent Gmbh carboxamide
KR20060130123A (en) 2003-12-22 2006-12-18 아스텔라스세이야쿠 가부시키가이샤 Ornithine derivatives as prostaglandin E2 agonists or antagonists
WO2007002639A2 (en) 2005-06-24 2007-01-04 Migenix Inc. Non-nucleoside anti-hepacivirus agents and uses thereof
US20080171783A1 (en) 2006-12-28 2008-07-17 Migenix Inc. Compositions and methods for treating hyperproliferative disease
EP2763962B1 (en) * 2011-10-07 2019-12-04 Cornell University Methods of treatment using modulators of sirt2

Also Published As

Publication number Publication date
EP2763962A1 (en) 2014-08-13
EP2763962B1 (en) 2019-12-04
CN103974934A (en) 2014-08-06
US9359293B2 (en) 2016-06-07
US9572789B2 (en) 2017-02-21
CN103974934B (en) 2019-07-23
US20140249216A1 (en) 2014-09-04
EP2763962A4 (en) 2015-08-19
CN110143900A (en) 2019-08-20
CN110143900B (en) 2021-08-03
ES2773266T3 (en) 2020-07-10
WO2013052727A1 (en) 2013-04-11
US20160279091A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
IN2014DN03077A (en)
BR112015000578A2 (en) complement pathway modulators and their uses
EA201590881A1 (en) THERAPEUTIC CONNECTIONS AND COMPOSITIONS AND THEIR USE AS MODULATORS PK-M2
EP4302764A3 (en) C17, c20, and c21 substituted neuroactive steroids and their methods of use
UA109916C2 (en) 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRRA1 ANTAGONISTS
EA201590118A1 (en) PYRROLIDINE DERIVATIVES AND THEIR APPLICATION AS MODULATORS OF THE COMPLEMENT ACTIVATION
EA201391561A1 (en) NEW CONNECTIONS-MODULATORS GPR-119
CO2018005315A2 (en) Modulators of the interaction of sestrina-gator2 and its uses
MX2013012896A (en) NEW COMPOUNDS AS PROTEIN KINASE MODULATORS.
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
EA201270720A1 (en) ANDROGEN RECEPTOR MODULATORS AND THEIR APPLICATION
EA201590053A1 (en) MODULATORS OF THE COMPLEMENT SYSTEM AND THEIR APPLICATION
WO2015010054A3 (en) Neuroactive steroids, compositions, and uses thereof
EA201491161A1 (en) FLUORINATED ESTROGEN RECEPTOR MODULATORS AND THEIR APPLICATION
MX392150B (en) CANABINOID RECEPTOR MODULATORS.
PH12015502161A1 (en) Therapeutic compounds and compositions
BR112015021999A2 (en) 2,3-dioxigenase indoleamine inhibitors (acid)
EP4360712A3 (en) Aryl- or heteroaryl-substituted benzene compounds
BR112014027359A2 (en) modulators of the complementary reaction series and uses thereof
EA201491530A1 (en) MODULATORS OF ESTROGEN RECEPTORS AND THEIR APPLICATION
EA201300471A1 (en) SUBSTITUTED 6-AMINONICOTINAMIDES AS KCNQ2 / 3 MODULATORS
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
CO2024013744A2 (en) nlrp3 modulators
MX2014010537A (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions.
BR112017016378A2 (en) monomethyl fumarate prodrug compositions